Genkyotex Announces FDA Approval of Phase 2 InvestigatorInitiated Trial with GKT831 in IPF

Genkyotex Announces FDA Approval of Phase 2 InvestigatorInitiated Trial with GKT831 in IPF

  • Study expands potential clinical indications for lead compound
  • Trial fully funded via a grant from the United States National Institutes of Health

Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX therapies, announced today that the United States Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application allowing the initiation of a Phase 2 trial of the Company’s lead product candidate, GKT831, in patients with idiopathic pulmonary fibrosis (IPF).

For more information,

https://www.genkyotex.com/images/PDF/GB/1_Press_Releases/2019/2019-07-17_GKTX_PR_LSA_EN_8cb75.pdf